These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34880628)

  • 21. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
    Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
    Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review.
    Zhang D; Huang J; Sun Y; Guo Q
    Onco Targets Ther; 2019; 12():3635-3644. PubMed ID: 31190866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study.
    Ding P; Yang P; Tian Y; Guo H; Liu Y; Zhang Z; Zheng T; Tan B; Zhang Z; Wang D; Li Y; Zhao Q
    J Gastrointest Oncol; 2021 Aug; 12(4):1416-1427. PubMed ID: 34532099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
    Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
    Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature.
    Xu M; Huang H; Xiong Y; Peng B; Zhou Z; Wang D; Yang X
    Oncol Lett; 2014 Jul; 8(1):291-294. PubMed ID: 24959263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
    Yan Y; Li H; Wu S; Wang G; Luo H; Niu J; Cao L; Hu X; Xu H; Jia W; Sun Y; Yao Y; Chen W; Ke L; Hu B; Ji C; Sun Y; Chen J; Li M; He Y
    Ann Transl Med; 2022 Feb; 10(4):205. PubMed ID: 35280426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
    Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
    Wu F; Zhang S; Gao G; Zhao J; Ren S; Zhou C
    Cancer Biol Ther; 2018 Mar; 19(3):141-144. PubMed ID: 29261000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
    Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
    [No Abstract]   [Full Text] [Related]  

  • 36. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
    Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.
    Luo H; Zhang L; Yang B; Feng Y; Xiong Y; Zhang S; Li X; Qian C; Dong W; Dai N
    Invest New Drugs; 2020 Feb; 38(1):148-159. PubMed ID: 31399906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Pautier P; Joly F; Kerbrat P; Bougnoux P; Fumoleau P; Petit T; Rixe O; Ringeisen F; Carrasco AT; Lhommé C
    Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    McNeish IA; Ledermann JA; Webber L; James L; Kaye SB; Hall M; Hall G; Clamp A; Earl H; Banerjee S; Kristeleit R; Raja F; Feeney A; Lawrence C; Dawson-Athey L; Persic M; Khan I
    Ann Oncol; 2014 Oct; 25(10):1988-1995. PubMed ID: 25070546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.